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Background
In a post-marketing analysis last updated in July 2007, the
FDA reported that an estimated 0.2% of patients suffered
treatment related anaphylaxis and rare incidence of serum
sickness. To substantiate this, the occurrence of treatment
related anaphylaxis and serum sickness in our large
Canadian allergy and asthma tertiary clinic was assessed.
Methods
A retrospective chart review of our database of omalizu-
mab administration between 1998 and June 2014 was
performed.
Results
During clinical trials and with our post market experi-
ence, between 1998 and June 2014, over 21,000 injec-
tions of omalizumab to more than 250 patients were
administered and no cases of anaphylaxis or serum sick-
ness like symptoms were observed.
Conclusion
Meticulous care was taken by our omalizumab adminis-
tration clinic to ensure optimal safety based on the
emphasized warnings of anaphylaxis, as well as, the indi-
cated warnings and precautions for serum sickness. Data
collected in this analysis observed no cases of anaphy-
laxis or serum sickness like symptoms in the treatment
of over 250 patients, during a period of 15.5 years, who
combined received 21,000 injections of omalizumab
thus confirming the low incidence of both anaphylaxis
and serum sickness.
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